SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of molecular
technologies designed to provide physicians with clinically
actionable information to improve the outcomes of patients
diagnosed with cancer, announces that Michael W. Nall, Biocept President and CEO, will
participate on the panel "COVID-19 Testing & Susceptibility
- Clearing the Air" hosted by Maxim Group and M-Vest on
Wednesday, May 27 beginning at
12:00 p.m. Eastern time (9:00 a.m. Pacific time).
The panel will include an interactive discussion moderated by
Jason McCarthy, Ph.D., Maxim Group
Senior Managing Director, Biotechnology. Among the topics to
be discussed are the availability of COVID-19 testing and types of
testing. The event is being held as the second installment in
Maxim Group's COVID-19 Virtual Conference Series.
To access the panel discussion, please RSVP at
Panel Discussion Details:
- Panel Session Title: Testing & Susceptibility
– Clearing the Air
- Date and Time: Wednesday,
May 27, 12:00 p.m. Eastern
time (9:00 a.m. Pacific
Biocept, Inc. is a molecular
diagnostics company with commercialized assays for lung, breast,
gastric, colorectal and prostate cancers, and melanoma. The Company
uses its proprietary liquid biopsy technology to provide physicians
with clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
View original content to download
SOURCE Biocept, Inc.